Comparing Cost of Revenue Efficiency: ADMA Biologics, Inc. vs Geron Corporation

A Tale of Two Biotech Companies: ADMA Biologics vs. Geron Corporation

In the competitive world of biotechnology, cost efficiency is a critical factor for success. Over the past decade, ADMA Biologics, Inc. and Geron Corporation have demonstrated contrasting trends in their cost of revenue. From 2014 to 2023, ADMA Biologics has seen a staggering increase of over 4,400% in its cost of revenue, peaking in 2023. This growth reflects their aggressive expansion and investment in production capabilities. In contrast, Geron Corporation's cost of revenue has fluctuated, with a notable dip in 2021 and 2022, where it fell to less than 1% of ADMA's costs. This could indicate a strategic shift or operational efficiencies. As these companies navigate the biotech landscape, their financial strategies offer valuable insights into their operational priorities and market positioning.